[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2026; 10: (2) ; 10.12208/j.ijcr.20260083 .

Study on the therapeutic value of rituximab injection combined with CHOP regimen for diffuse large B-cell lymphoma
利妥昔单抗注射液加CHOP方案对弥漫性大B细胞淋巴瘤的治疗价值研究

作者： 韦红梅 *

广西省河池市中医医院 广西河池

*通讯作者： 韦红梅,单位：广西省河池市中医医院 广西河池；

引用本文: 韦红梅 利妥昔单抗注射液加CHOP方案对弥漫性大B细胞淋巴瘤的治疗价值研究[J]. 国际临床研究杂志, 2026; 10: (2) : 96-98.
Published: 2026/2/12 9:15:33

摘要

目的 分析在弥漫性大B细胞淋巴瘤患者中应用利妥昔单抗注射液加CHOP方案的医学价值。方法将2023年1月-2025年12月内就诊的弥漫性大B细胞淋巴瘤60例以药物治疗方案不同分30例对照组CHOP方案，30例观察组增加利妥昔单抗注射液。对比治疗效果、癌症生活质量评分以及不良反应。结果 观察组治疗效果优于对照组，且生活质量评分优于对照组对比有统计学意义（P＜0.05）。两组不良反应对比差异不具有统计学意义（P＞0.05）。结论 利妥昔单抗注射液加CHOP方案对弥漫性大B细胞淋巴瘤可提高治疗效果，但不增加不良反应，能让患者生活质量提高，让其受益。

关键词： 利妥昔单抗注射液；CHOP方案；弥漫性大B细胞淋巴瘤；免疫应答

Abstract

Objective To analyze the medical value of using rituximab injection plus CHOP regimen in patients with diffuse large B-cell lymphoma.
Methods 60 cases of diffuse large B-cell lymphoma treated between January 2023 and December 2025 were divided into a control group (CHOP group) and an observation group (observation group) with different drug treatment regimens, with 30 cases receiving CHOP regimen and 30 cases receiving rituximab injection. Compare treatment efficacy, cancer quality of life score, and adverse reactions.
Results The treatment effect of the observation group was better than that of the control group, and the quality of life score was significantly better than that of the control group (P<0.05). The difference in adverse reactions between the two groups was not statistically significant (P>0.05).
Conclusion   The combination of rituximab injection and CHOP regimen can improve the therapeutic effect of diffuse large B-cell lymphoma without increasing adverse reactions, which can improve the quality of life of patients and benefit them.

Key words： Rituximab injection; CHOP regimen; Diffuse large B-cell lymphoma; Immune response

参考文献 References

[1] 徐志秀,李卓然,李青,等.基于SEER数据库的原发中枢神经系统弥漫性大B细胞淋巴瘤疾病特异性死亡危险因素[J].河南医学研究,2025,34(18):3283-3287.

[2] 何柳,顾程,胡斌,等.基线18F-氟脱氧葡萄糖PET/CT预测弥漫性大B细胞淋巴瘤预后的临床价值[J].实用放射学杂志,2025,41(09):1557-1561.

[3] 张馨雨,于兴泰,胡哲铭,等.177Lu-DOTA-RTX靶向放射性核素药物的制备及其抗弥漫性大B细胞淋巴瘤初步研究[J].中南药学,2025,23(08):2151-2156.

[4] 陈明珍,丁如欣,万志影,等.脂肪干细胞调控CHOP/Bcl-2通路缓解犬急性胰腺损伤[J].中国兽医学报,2025, 45(11):2500-2506.

[5] 惠晓培,王颖,靳迎.利妥昔单抗联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及预后分析[J].实用癌症杂志,2025,40(09):1502-1504+1519.

[6] 程铃,刘嫚,杨威,等.利妥昔单抗滴速过快致甲状腺眼病患者视力损伤1例分析[J/OL].中国医院药学杂志,1-5[2025-12-10].

[7] 陈垚池,邹东梅,胡蓉华,等.奥妥珠单抗注射液联合化疗致急性重度血小板减少症1例分析[J/OL].中国药物警戒,1-4[2025-12-10].

[8] 周孝会,孙艳芬.利妥昔单抗联合环磷酰胺治疗难治性肾病综合征患者的效果[J].中国民康医学,2025,37(08):48-50.

[9] 张艳鹏,吕洁萍.瑞马唑仑通过PERK/ATF4/CHOP通路对老年大鼠术后认知功能及神经突触的影响[J].河北医学,2025,31(10):1619-1625.

[10] 梁秋,黄忠光,朱妮娜.糖皮质激素联合小剂量利妥昔单抗注射液治疗难治性原发性免疫性血小板减少症的效果及不良反应发生率[J].吉林医学,2024,45(12):3075-3078.